Vivus is a biopharmaceutical company that develops innovative, next-generation therapies to address unmet needs of individuals with obesity, diabetes, sleep apnea and sexual health for the United States, Europe and other world markets.
For those of you not familiar, a biopharmaceutical also referred to as a biologic can be any pharmaceutical drug product that is manufactured in, extracted from, or semi synthesized from a biological system.
Vivus is a relatively small pharmaceutical company that is headquartered in Mountain View, California. They recently developed an erectile dysfunction (ED) drug know as Avanafil. Avanafil has completed Phase 3 trials and has been approved by the FDA and will be sold under the name Stendra. Stendra is the first and only oral ED therapy approved to be taken about 15 minutes before sexual activity.
Vivus has also developed an obesity drug known as Qnexa which is now known as Qsymia. It is a combination of phentermine and topiramate. Phentermine and topiramate are known as weight loss drugs. Qsymia was approved by the U.S. Food and Drug Administration (FDA) in mid 2012. Qsymia is an extended release capsule that acts as an appetite suppressant that decreases your craving for food thereby decreasing your daily caloric intake allowing you to lose weight. The drug was approved for individuals with a BMI of 27 or greater who have at least one weight-related condition such as diabetes type-2, high cholesterol or high blood pressure.
The Medical Affairs Department of Vivus bridges research, clinical development, scientific publications, health outcomes, bio-statistics, medical education and many other medical services. They provide health care professionals, key opinion leaders, regulatory agencies, professional agencies and groups as well as physicians with medical and scientific information about education. Vivus created the most popular diet pill with Phentermine in the world – Qsymia, combination of Phentermine and Topiramate.